We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Electric Pulses May Help Treat Pancreatic Cancer

By HospiMedica International staff writers
Posted on 11 Apr 2012
Minimally invasive percutaneous irreversible electroporation (IRE) may help make surgery an option for unresectable, locally advanced pancreatic cancer patients, according to a new study.

Researchers at the University of Miami (FL, USA) reviewed the records of eight patients (aged 51-72 years) with locally advanced pancreatic adenocarcinomas (LAPCs) who were referred for IRE that was performed between December 2010 and September 2011; all the patients had prior chemotherapy, and seven had prior radiation. More...
The procedures were done percutaneously under general anesthesia (GA) using a standard protocol in all patients. The primary endpoint was safety, and the secondary endpoints included survival and resection rate after procedure.

The results showed that out of the original eight inoperable individuals, two went on to have surgery. Both had successful resections and remained disease-free at two and six months after resection, respectively. Among the six remaining patients, two were lost to follow-up and one had progressive disease after three months. One patient had a negative follow-up positron emission tomography (PET) scan and surgery was planned; the two remaining patients were under follow-up to determine resectability. The study was presented at the Society of Interventional Radiology (SIR) 37th annual scientific meeting, held during March 2012 in San Francisco (CA, USA).

“Without IRE, these people are essentially left with chemotherapy and radiation therapy. At this point the prognosis for this group is pretty dismal and they have an estimated survival of less than one year,” said lead author and study presenter Govindarajan Narayanan, MD, of the division of vascular/interventional radiology, and colleagues. “With this procedure, there is the potential to have the tumor peeled off the blood vessels, and follow up treatment to repair the affected area of the pancreas.”

IRE uses microsecond electrical pulses to force open and destroy tumor cells around a vast and delicate network of blood vessels. The technique has been successful in treating primary and metastatic liver cancer, and IRE is now in the first stages of implementation as a treatment for pancreatic cancer. The procedure is performed using the NanoKnife Tissue Ablation system, a product of AngioDynamics (Latham, NY, USA).

Related Links:

University of Miami
AngioDynamics



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.